•  
  •  
 

Document Type

Article

Media Type

Text

Abstract

In June 2013, in Ass'n for Molecular Pathology et. al., v. Myriad Genetics, Inc., the Supreme Court examined the patent eligibility of isolated (human) DNA and its components. This was in response to advances in breast cancer prescreening surrounding mutations associated with the BRCA1 and BRCA2 genes. In accordance with 35 U.S.C. §101, the Court evaluated whether naturally occurring segments of DNA and synthetically created segments of v DNA were patent eligible. The Court found that while isolated natural DNA segments were patent ineligible, synthetically created DNA segments were not precluded. This Note examines the potential economic and ethical implications of this decision and focuses a discussion on why such a ruling may likely prove contradictory. While the synthetically created DNA evaluated in Myriad, known as complimentary DNA (cDNA), is in fact synthetic and generated at the hand of a laboratory technician, arguably the one who holds the patent on such a component of DNA will therefore be able to exert increased control over the naturally occurring DNA segment for which the cDNA serves to compliment.

First Page

205

Last Page

230

Publication Date

9-1-2014

Department

College of Law

ISSN

0734-1490

Language

eng

Publisher

Northern Illinois University Law Review

Included in

Law Commons

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.